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ABSTRACT 
 
Background 
Previous investigations in adult smokers from the COPDGene Study have shown that early-life 
respiratory disease is associated with reduced lung function, COPD, and airway thickening. Using five-
year follow-up data we assessed disease progression in subjects with early-life respiratory disease. We 
hypothesized that there are alternative pathways to reaching reduced FEV1 and subjects with childhood 
pneumonia, childhood asthma, or asthma-COPD overlap (ACO), would have less lung function decline 
than subjects without these conditions. 
 
Methods 
Subjects returning for five-year follow-up were assessed. Childhood pneumonia was defined by self-
reported pneumonia at <16 years. Childhood asthma was defined as self-reported asthma diagnosed by a 
health-professional at <16 years. ACO was defined as COPD subjects with self-reported asthma 
diagnosed by a health-professional at ≤40 years. Smokers with and without these early-life respiratory 
diseases were compared on measures of disease progression.  
 
Results 
Follow-up data from 4,915 subjects was examined, including 407 childhood pneumonia subjects, 323 
childhood asthmatics, and 242 ACO subjects. History of childhood asthma or ACO was associated with 
in increased exacerbation frequency (childhood asthma p<0.001;ACO p=0.006), and odds of severe 
exacerbations (childhood asthma OR1.41;ACO OR1.42). History of childhood pneumonia was associated 
with increased exacerbations in COPD subjects (β=0.17;p=0.04). None of these early-life respiratory 
diseases were associated with increased rate of lung function decline or progression on CT scan. 
   
Conclusions 
Subjects with early-life asthma are at increased risk of developing COPD, and having more active disease 
with more frequent and severe respiratory exacerbations, without increased rate of lung function decline 
over a five-year period.   
 
CLINICAL TRIAL REGISTRATION 
ClinicalTrials.gov, NCT00608764 (Active since January 28, 2008) 
https://clinicaltrials.gov/ct2/show/NCT00608764 
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INTRODUCTION 
 
Early life respiratory conditions, including pneumonia and asthma, increase risk for developing chronic 
obstructive pulmonary disease (COPD).1-5 Classically, COPD is thought of as a disease of adult smokers, 
characterized by rapid lung function decline.3,6 An emerging subtype of COPD is being defined in a 
subset of subjects who, due to childhood respiratory disease, never achieve the expected maximal FEV1 in 
young adulthood.1,5,7 These patients are more likely reach the diagnostic threshold for COPD even with 
normal age-related lung function decline.3 Understanding progression of COPD in this population will be 
an important factor in personalizing management and treatment plans.   
 
We have previously examined subjects with childhood pneumonia, childhood asthma, and asthma-COPD 
overlap (ACO) in Phase 1 of COPDGene, a multicenter observational cohort of adult smokers.1,8-10 
Childhood pneumonia was associated with reduced lung function, COPD, and increased airway disease 
on chest computed tomography (CT).1 Childhood asthma was associated with smaller segmental airways.9 
ACO subjects were younger with a lower lifetime smoking intensity, but similar FEV1 reductions as non-
ACO COPD subjects, implying an additional mechanism for their reduced lung function.  
 
The current study used five-year follow-up data from Phase 2 of COPDGene to examine disease 
progression in three independent subject groups of current and former smokers: childhood pneumonia, 
childhood asthma, and ACO. We hypothesized that these early life respiratory diseases will identify 
subjects with less lung function decline at the time of five-year follow-up. To assess this, we have 
independently compared subjects from this cohort in three separate analyses (1) subjects with versus 
without childhood pneumonia, (2) subjects with versus without childhood asthma, and (3) subjects with 
ACO versus those with COPD alone (e-Figure 1). 
 
MATERIALS AND METHODS 
 
Study Subjects 
COPDGene enrolled 10,199 current and former smokers with and without COPD in Phase 1 from 2008–
2011. This investigation evaluates the first 4,915 subjects returning for five-year follow-up in Phase 2 
(September 24,2016 data set) (e-Figure1). This study was approved by the Institutional Review Boards at 
each of the twenty-one clinical sites and all participants provided written informed consent.10 At 
enrollment subjects were 45–80 years old, non-Hispanic white or African American, and had at least a 10 
pack-year smoking history. Subjects were excluded if they had history of lung disease other than COPD 
or asthma, if they were nonsmokers, or if they had undergone lung transplant or lung volume reduction 
surgery. Study protocol, enrollment criteria, and data collection forms were previously described and are 
available at www.copdgene.org.10,11  
 
Participants completed a modified American Thoracic Society Respiratory Epidemiology Questionnaire, 
Modified Medical Research Council dyspnea scale, and questionnaires related to demographics and 
medical history.11-13 Quality of life was assessed using the St. George's Respiratory Questionnaire 
(SGRQ) with permissions obtained for instrument use.14 Subjects completed a standardized spirometry 
protocol (ndd EasyOne Spirometer, Zurich, Switzerland) before and after albuterol.  Quantitative image 
analysis used Thirona software (www.thirona.eu). Inspiratory and expiratory chest CT scans were 
available for 72% and 62% of Phase 2 participants, respectively. Emphysema was quantified by 
inspiratory scan low-attenuation areas < -950 Hounsfield units (HU), and by the adjusted density of lung 
HU below which 15% of the voxels had the lowest attenuation numbers at full inspiration. Gas trapping 
was quantified on expiratory scan at < -856 HU . Parametric response mapping (PRM) paired inspiratory 
and expiratory CT images to define emphysema, and to assess functional small airways disease as a 
measure of non-emphysematous air trapping.15 Airway measurements assessed the square root of the wall 
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area of a hypothetical airway with 10mm internal perimeter (SRWA-Pi10) and were available for 20% of 
participants.16,17 
 
Statistical Analysis 
Childhood pneumonia was defined by self-report of first pneumonia at < 16 years or during childhood.1 
Childhood asthma was defined as self-report of asthma diagnosed by a health professional with age of 
onset at < 16 years or during childhood.118 ACO was defined as subjects with COPD who self-reported 
asthma diagnosed by a health professional with age of onset at ≤ 40 years or during childhood.1,8,18,19  
COPD was defined as Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2007 spirometry 
grades 2-4, corresponding to post-bronchodilator forced expiratory volume in the first second (FEV1) to 
forced vital capacity (FVC) ratio < 0.7 with FEV1 < 80% predicted.20  
 
Mortality data was compiled using the social security death index through the COPDGene Longitudinal 
Follow-up Program (September 2016 dataset). Interval development of  COPD diagnosis was defined if a 
subject did not have GOLD grade 2-4 COPD at visit 1 but did at visit 2. Chronic bronchitis was defined 
by cough and phlegm production lasting at least three months per year for at least two years. Respiratory 
exacerbations were defined by use of antibiotics and/or systemic steroids for an acute respiratory illness. 
Severe exacerbations required an emergency room visit or hospitalization.   
 
We performed three independent comparisons: (1) subjects with versus without childhood pneumonia, (2) 
subjects with versus without childhood asthma, and (3) subjects with ACO versus COPD alone (e-Figure 
1). Demographics, respiratory symptoms/diseases, lung function, and chest CT scan measurements were 
assessed using R v3.1.1. Tests used and covariates adjusted for are detailed in Tables 1-4 and supplement 
e-Tables 1-2. Multivariable analyses used logistic regression, linear regression, or linear mixed models. 
Linear mixed models assessed two measures per subject, comparing visits 1 and 2, with intercept 
computed at the level of subject, the only variable considered as a random effect. Subjects with missing or 
unclassifiable responses were removed from specific analyses.  
 
To assess association with COPD exacerbations, a sensitivity analysis was performed among only the 
subset of subjects who had GOLD Stage 2-4 COP  at the time of initial enrollment. Exacerbation 
severity, frequency, and rate of lung function decline were compared independently in COPD subjects 
with and without childhood pneumonia, and those with and without childhood asthma. 
 
RESULTS 
 
Subject classification and characteristics 
Of 10,199 adult smokers enrolled, 857 (8.4%) had childhood pneumonia, 730 (7.2%) had childhood 
asthma and 569 (5.6%) had ACO (Table 1, e-Table 1). Five-year follow-up data on 4,915 subjects was 
examined; 19 subjects who had undergone interval lung transplant or lung volume reduction surgery were 
excluded. Disease progression analysis in Phase 2 included 407 (47%) of childhood pneumonia subjects, 
323 (44%) of childhood asthmatics and 242 (43%) of ACO subjects. Overlap between subject 
classifications can be seen in Figure 1. Childhood pneumonia subjects were older, more likely to be non-
Hispanic white, and had a longer smoking history compared to subjects without childhood pneumonia. 
Childhood asthma subjects were younger and more likely to be African American than those without 
childhood asthma. ACO subjects were more likely to be younger, female, African American, and have 
fewer pack-years smoking than COPD subjects without ACO. 
 
Mortality 
Of 10,199 adult smokers enrolled at Phase 1, mortality data was available for 8,901 (87%). Deceased 
subjects included 116 (14%) childhood pneumonia subjects, 84 (12%) of childhood asthmatics, and 103 
(18%) of ACO subjects (e-Figure 1). There were no statistically significant differences in mortality 
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among subjects with childhood pneumonia, childhood asthma, or ACO in analysis adjusted for gender, 
age, race, FEV1, pack-years smoking, and current smoking (p>0.5 for all analyses).  
 
Disease Progression  
Supplemental e-Table 1 shows univariate associations with childhood pneumonia, childhood asthma, and 
ACO. In multivariable models, childhood pneumonia was not associated with disease progression by lung 
function, clinical symptoms including severity and frequency of respiratory exacerbations, or chest CT 
scan measurements of emphysema and airway disease (Table 2).  
 
Compared to those without childhood asthma, subjects with childhood asthma had increased frequency of 
respiratory exacerbations (β=0.22 exacerbations/year; p<0.001) and increased odds ratio of having had a 
severe exacerbation in the prior year (OR 1.41;95%CI 1.00-1.96) (Table 3). Subjects with childhood 
asthma showed less FVC decline (β=58.44ml;p=0.02) and borderline significance for less FEV1 decline 
(β=32.10ml;p=0.053). Childhood asthmatics had a statistically significant, but not clinically significant, 
improvement in quality of life based on improvement in SGRQ total score (β=-2.40 points;p=0.01).21 On 
chest CT, there were no differences in progression of emphysema and airway disease. 
 
Compared to subjects with COPD only, ACO subjects had increased frequency of exacerbations (β=0.20 
exacerbations/year;p=0.006) and increased odds of a severe exacerbation (OR 1.42;95%CI 1.00-2.00) 
(Table 4). They had a statistically but not clinically significant improvement in SGRQ total score (β=-
2.89 points;p=0.007). There was no difference in the rate of decline in FEV1 or FVC. On chest CT, ACO 
subjects had less progression of emphysema and air trapping compared to COPD subjects, but no 
difference in progression of airway wall thickening.  
 
Sensitivity Analysis 
There were 1,613 subjects with GOLD stage 2-4 COPD at enrollment who returned for five-year follow-
up. Among COPD subjects, a history of childhood pneumonia was associated with increased frequency of 
respiratory exacerbations (β=0.17;p=0.04) when compared to subjects without childhood pneumonia (e-
Table 2); there was no significant increase in severe exacerbations or the rate of lung function decline. 
COPD subjects with childhood asthma did not have increased frequency or severity of respiratory 
exacerbations when compared to those without childhood asthma; there was an association with slower 
rate of decline in FVC (β=91.64ml;p=0.04).   
 
DISCUSSION 
 
This investigation used five-year follow-up data from 4,915 adult smokers to examine disease activity and 
progression independently in those with childhood pneumonia, childhood asthma, and ACO. Childhood 
asthma and ACO were associated with increased disease activity, with more frequent and severe 
exacerbations, but not with disease progression defined by lung function decline and chest CT changes. 
Childhood asthmatics had less lung function decline, and ACO subjects had less progression of CT 
emphysema and air trapping. Childhood pneumonia was associated with increased respiratory 
exacerbations among COPD subjects, with no increase in the rate of lung function decline. 
 
We have previously established that, in adult smokers from COPDGene, early life respiratory diseases are 
associated with reduced lung function and COPD.1,8,9,18 Childhood pneumonia was associated with 
increased odds of developing COPD (OR 1.40;95%CI 1.17-1.66), with the greatest risk among those with 
asthma and pneumonia in childhood (OR 1.85;95%CI 1.10-3.18).1 Childhood asthma was associated with 
smaller segmental airways, which was a risk for decreased FEV1 and chronic airflow obstruction.9 ACO 
subjects, compared to those with COPD alone, were younger, with lower lifetime smoking intensity, and 
increased exacerbation frequency.8,18   
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Other cohorts have shown that asthma and wheezy bronchitis are associated with COPD risk.22 In the 
Childhood Asthma Management Program, 11% of 1,041 participants met spirometric criteria for COPD 
by age 30, and analysis of lung growth trajectories showed a subset with reduced lung growth.5 The 
Aberdeen WHEASE cohort followed 330 subjects to age 61, showing that childhood asthma and wheeze 
were associated with COPD development.23 The Melbourne Asthma Cohort found that childhood asthma 
conferred a thirty-two-fold adjusted odds of developing COPD. In 45 year follow-up among 1,389 
Tasmanian children, low childhood lung function was associated with COPD and ACO.24 These 
associations are likely due to reduced lung growth in patients with childhood respiratory disease causing a 
decrease in maximally attained lifetime FEV1, and increasing probability that natural decline in lung 
function will lead to diagnostic levels of COPD. This concept is supported by prior description of lung 
function trajectories, which showed that current and former smokers with low FEV1 in early adulthood 
can develop COPD based only on natural lung function decline.7  
 
In this study, childhood asthmatics and ACO subjects were frequent exacerbators, yet did not have 
significantly increased rate of  lung function decline or emphysema progression at five-year follow-up. 
This is contrary to previous descriptions of frequent exacerbators in COPDGene where there was an 
association between frequent exacerbations and excess FEV1 decline.25  This difference is likely due to 
the fact that in our current study we examined frequent exacerbators who were early life asthmatics. 
Asthmatic subjects may have different drivers of exacerbations than usual COPD subjects, as well as a 
slower rate of lung function decline. Our current investigation of disease progression in asthmatics 
supports work from the European Community Respiratory Health survey examining 218 ACO subjects 
and showing they had less FEV1 decline than COPD subjects at 4-12 year follow-up, but higher 
hospitalization rates.26 Similarly, in 55 subjects from an Australian cohort, ACO was not associated with 
longitudinal lung function decline over four years.27  
 
This study expands our understanding of the natural history of COPD in smokers with childhood 
respiratory disease, and highlights the significance of early life asthma. Early life asthma is a known risk 
factor for developing COPD. Our study reveals that disease progression is distinctly different for these 
subjects, who experience more frequent and severe exacerbations, but without significantly increased rate 
of lung function decline. In fact, these subjects appeared to be protected from decline in lung function 
(childhood asthma) or progression of emphysema (ACO). In a sensitivity analysis looking at only subjects 
with COPD, childhood pneumonia was associated with more frequent exacerbations without any 
difference in rate of lung function decline, and childhood asthma was associated with less FVC decline. 
 
This study is limited by the use of self-reported history of pneumonia and asthma. Ideally, medical 
records of diagnoses would be available; however, in this large study of adult subjects, this would have 
required childhood records, which was not feasible. Self-reported diagnosis has been shown to be 
effective at revealing meaningful subsets of subjects with early life respiratory disease in our prior 
investigations in this cohort, which have included sensitivity analysis for recall bias.1,8,9,28 It would be 
optimal to examine disease progression in non-smokers, however, this COPDGene investigation did not 
include data on non-smokers. This is an important area for future investigation.  
 
This study examines disease progression at five-year follow-up in approximately half of the original 
cohort. A limitation in this population with significant morbidity is a concern for selection bias. Ideally, 
we would include all original subjects in longitudinal analysis. Of the original 10,199 subjects enrolled, 
6,056 (59%) have been accounted for, including 1,141 deaths, and 4,915 subjects with Phase 2 data; 
additional efforts are ongoing to bring back more subjects. The CT analysis is limited by data being 
available only for a subset of Phase 2 subjects, which particularly affected SRWA-Pi10 data.   
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CONCLUSIONS 
We demonstrate that among a population of adult smokers, early life asthmatics have more active 
respiratory disease, with increased frequency and severity of exacerbations, but without increased rate of 
lung function decline or disease progression on chest CT.22 Early life respiratory diseases are known risk 
factors for developing COPD.1-5 COPD in these populations is likely due to lung development progressing 
along a reduced lung growth trajectory, with maximal expected FEV1 never being achieved. Thus, these 
subjects are at risk for reaching the level of COPD even with only typical lung function decline associated 
with aging. This investigation elucidates the expected course of COPD in at-risk populations, showing 
that early life respiratory diseases are risk factors for active disease without lung function decline. This 
supports the idea that there is an alternative pathway to reach COPD in smokers with early life respiratory 
disease, suggesting a subtype of COPD with a different mechanism of reduced FEV1. These asthmatic 
subjects additionally may have different drivers of respiratory exacerbations, and a better understanding 
this relationship could promote different therapeutic considerations, allowing increased precision in 
COPD treatment. 
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TABLES 
 
Table 1: COPDGene Phase 2 Subject Characteristics               
  
Childhood 
Pneumonia 
No Childhood 
Pneumonia P-value 
Childhood 
Asthma 
No Childhood 
Asthma P-value 
Asthma-COPD 
Overlap COPD P-value 
Phase 1 Subjects (%) N = 857 N = 9306   N = 730 N = 9417   N = 569 N = 3110   
Phase 2 Subjects (%) 407 (47%) 4491 (48%) 0.69 323 (44%) 4563 (48%) 0.03 242 (43%) 1359 (44%) 0.64 
Male gender (%)a 202 (50%) 2269 (51%) 0.77 157 (49%) 2312 (51%) 0.51 107 (44%) 760 (56%) 0.001 
Mean age, year (SD)c 67 (8) 65 (9) <0.001 64 (8) 66 (9) <0.001 65 (8) 69 (8) <0.001 
Non-Hispanic white (%)a 350 (86%) 3165 (70%) 
<0.001 200 (62%) 3305 (72%) <0.001 157 (65%) 1099 (81%) <0.001 
African American (%)a 57 (14%) 1326 (30%) 123 (38%) 1258 (28%) 85 (35%) 260 (19%) 
Pack-years of smoking (SD)b 50 (27) 44 (24) <0.001 43 (23) 44 (24) 0.21 46 (24) 53 (26)  <0.001 
Current smoking (%)a 134 (33%) 1698 (38%) 0.06 125 (39%) 1707 (37%) 0.69 82 (34%) 390 (29%) 0.12 
COPD at enrollment (%)a 175 (54%) 1429 (41%) <0.001 152 (61%) 1446 (40%) <0.001 242 (100%) 1359 (100%) NA 
Abbreviations: COPD Chronic Obstructive Pulmonary Disease, SD standard deviation. Univariate analysis with a Chi-square b Wilcoxon rank sum test c t-test. 
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Table 2: Disease Progression in Childhood Pneumonia           
  Childhood  No Childhood       Impact of Childhood Pneumoniaa 
  Pneumonia Pneumonia OR 95% CI P-value 
  N = 407 N = 4491       
Developed COPD (%)b,e,f 30 (7%) 313 (7%) 1.04 (0.69, 1.52) 0.84 
Developed oxygen requirement (%)b.e.f 32 (8%) 286 (6%) 1.09 (0.73, 1.59) 0.66 
Developed chronic bronchitis (%)b,e,f,h 31 (8%) 359 (8%) 0.92 (0.61, 1.33) 0.66 
Had a severe COPD exacerbation in prior yr (%)b,e,f,g,h 48 (12%) 411 (9%) 1.23 (0.87, 1.71) 0.23 
      β SE P-value 
Number of COPD exacerbations in prior yr, mean (SD)c,e,f,g,h 0.42 (0.86) 0.30 (0.79) 0.06 0.04 0.10 
FEV1 post-BD % predicted, mean ∆ (SD)d,e -1.64 (11) -1.98 (11) 0.33 0.55 0.54 
FEV1 post-BD mL, mean ∆ (SD)d,e,f,i -196 (279) -202 (287) 8.32 15.03 0.58 
FVC post-BD % predicted, mean ∆ (SD)d,e -1.83 (12) -2.11 (12) 0.30 0.62 0.63 
FVC post-BD mL, mean ∆ (SD)d,e,f,i -250 (417) -248 (424) 3.56 22.52 0.87 
St. George’s Respiratory Questionnaire score, mean ∆ (SD)d,e,f,g -0.57  (17) 0.29 (15) model does not converge 
Modified Medical Research Council dyspnea scale, mean ∆ (SD)d,e,f,g -0.05 (1.13) 0.07 (1.24) -0.11 0.06 0.09 
6 minute walk distance in feet, mean ∆ (SD)d,e,f,g -154 (333) -129 (363) -23.90 18.85 0.21 
CT Scan Measuresk           
Emphysema Progression 
     
          PRM Emphysema % at -950 HU, mean ∆ (SD)d,e,f,h,j 0.45 (4) 0.71 (3) -0.03 0.20 0.86 
          Adjusted density, mean ∆ (SD)d,e,f,h,j -0.05 (12) -0.83 (11) -0.33 0.50 0.51 
Air Trapping Progression 
     
          Gas Trapping %, expiratory scan at -856 HU, mean ∆ (SD)d,e,f,h,j 1.14 (9) 1.21 (9) 0.48 0.51 0.34 
          PRM functional small airway disease, mean ∆ (SD)d,e,f,h,j    1.09 (7) 0.92 (7) 0.56 0.43 0.19 
Airway Thickening Progression 
     
          SRWA-Pi10 (SD), mean ∆ (SD)d,e,f,h,j 0.06 (0.29) 0.04 (0.30) 0.02 0.03 0.57 
Abbreviations: COPD chronic obstructive pulmonary disease; yr year; SD standard deviation; FEV1 forced expiratory volume in the first second; BD 
bronchodilator; FVC forced vital capacity; CT computed tomography; PRM parametric response mapping; HU Hounsfield units;  SRWA-Pi10 square root wall 
area of a hypothetical airway with 10mm internal perimeter. a Each row is a separate model: b Logistic regression with odds ratio (OR), 95 % confidence interval 
(CI); c Linear regression and d Linear mixed model with beta coefficient (β), standard error (SE). Adjusted for: e pack-years of smoking; f gender, age, race; g 
FEV1 % predicted; h current smoking; i height; j scanner model, BMI; k data available for only a portion of the population. 
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Table 3: Disease Progression in Childhood Asthma            
  Childhood  No Childhood  Impact of Childhood Asthmaa  
  Asthma Asthma OR 95% CI P-value 
  N = 323 N = 4563       
Developed COPD (%)b,e,f 27 (8%) 317 (7%) 1.22 (0.80, 1.81) 0.34 
Developed oxygen requirement (%)b.e.f 23 (7%) 295 (6%) 1.26 (0.78, 1.92) 0.31 
Developed chronic bronchitis (%)b,e,f,h 28 (9%) 359 (8%) 1.26 (0.82, 1.87) 0.27 
Had a severe COPD exacerbation in prior yr (%)b,e,f,g,h 52 (16%) 406 (9%) 1.41 (1.00, 1.96) 0.04 
      β SE P-value 
Number of COPD exacerbations in prior yr, mean (SD)c,e,f,g,h 0.59 (1.08) 0.29 (0.77) 0.22 0.04 <0.001 
FEV1 post-BD % predicted, mean ∆ (SD)d,e -1.48 (12) -1.98 (10) 0.47 0.60 0.44 
FEV1 post-BD mL, mean ∆ (SD)d,e,f,i -168 (303) -204 (284) 32.10 16.61 0.05 
FVC post-BD % predicted, mean ∆ (SD)d,e -0.73 (13) -2.15 (12) model does not converge 
FVC post-BD mL, mean ∆ (SD)d,e,f,i -188 (432) -252 (421) 58.44 24.84 0.02 
St. George’s Respiratory Questionnaire score, mean ∆ (SD)d,e,f,g -2.22 (18) 0.39 (15) -2.40 0.88 0.01 
Modified Medical Research Council dyspnea scale, mean ∆ (SD)d,e,f,g -0.02 (1.26) 0.07 (1.23) -0.08 0.07 0.25 
6 minute walk distance in feet, mean ∆ (SD)d,e,f,g -151 (385) -130 (360) -27.21 20.93 0.19 
CT Scan Measuresk           
Emphysema Progression 
     
          PRM Emphysema % at -950 HU, mean ∆ (SD)d,e,f,h,j 0.61 (4) 0.68 (3) -0.29 0.23 0.20 
          Adjusted density, mean ∆ (SD)d,e,f,h,j -1.33 (12) -0.72 (11) 0.17 0.58 0.77 
Air Trapping Progression 
     
          Gas Trapping %, expiratory scan at -856 HU, mean ∆ (SD)d,e,f,h,j 1.19 (9) 1.19 (9) -0.78 0.60 0.20 
          PRM functional small airway disease, mean ∆ (SD)d,e,f,h,j    0.97 (8) 0.93 (7) -0.41 0.51 0.42 
Airway Thickening Progression 
     
          SRWA-Pi10 (SD), mean ∆ (SD)d,e,f,h,j 0.07 (0.33) 0.04 (0.30) 0.03 0.04 0.41 
Abbreviations: COPD chronic obstructive pulmonary disease; yr year; SD standard deviation; FEV1 forced expiratory volume in the first second; BD 
bronchodilator; FVC forced vital capacity; CT computed tomography; PRM parametric response mapping; HU Hounsfield units;  SRWA-Pi10 square root wall 
area of a hypothetical airway with 10mm internal perimeter. a Each row is a separate model: b Logistic regression with odds ratio (OR), 95 % confidence interval 
(CI); c Linear regression and d Linear mixed model with beta coefficient (β), standard error (SE). Adjusted for: e pack-years of smoking; f gender, age, race; g 
FEV1 % predicted; h current smoking; i height; j scanner model, BMI; k data available for only a portion of the population. 
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Table 4: Disease Progression in Asthma-COPD Overlap (ACO)           
                 Impact of ACOa 
  ACO COPD OR 95% CI P-value 
  N = 242 N = 1359       
Developed oxygen requirement (%)b.e.f 33 (14%) 207 (15%) 0.97 (0.64, 1.45) 0.90 
Developed chronic bronchitis (%)b,e,f,h 24 (10%) 155 (11%) 0.90 (0.55, 1.42) 0.67 
Had a severe COPD exacerbation in prior yr (%)b,e,f,g,h 60 (25%) 237 (17%) 1.42 (1.00, 2.00) 0.05 
      β SE P-value 
Number of COPD exacerbations in prior yr, mean (SD)c,e,f,g,h 0.81 (1.23) 0.56 (1.03) 0.20 0.07 0.006 
FEV1 post-BD % predicted, mean ∆ (SD)d,e -2.53 (11) -2.64 (11) 0.10 0.76 0.89 
FEV1 post-BD mL, mean ∆ (SD)d,e,f,i -160 (313) -188 (306) 22.70 21.73 0.30 
FVC post-BD % predicted, mean ∆ (SD)d,e -2.81 (14) -3.69 (14) 0.84 0.97 0.39 
FVC post-BD mL, mean ∆ (SD)d,e,f,i -239 (466) -314 (506) 65.68 35.85 0.07 
St. George’s Respiratory Questionnaire score, mean ∆ (SD)d,e,f,g -1.09 (17) 1.84 (15) -2.89 1.06 0.007 
Modified Medical Research Council dyspnea scale, mean ∆ (SD)d,e,f,g 0.09 (1.26) 0.22 (1.29) -0.13 0.09 0.16 
6 minute walk distance in feet, mean ∆ (SD)d,e,f,g -156 (356) -189 (370) 23.60 25.94 0.36 
CT Scan Measuresk           
Emphysema Progression      
          PRM Emphysema % at -950 HU, mean ∆ (SD)d,e,f,h,j 1.14 (5) 2.14 (5) -0.97 0.41 0.02 
          Adjusted density, mean ∆ (SD)d,e,f,h,j -2.05 (11) -3.32 (11) 1.27 0.67 0.06 
Air Trapping Progression      
          Gas Trapping %, expiratory scan at -856 HU, mean ∆ (SD)d,e,f,h,j 1.57 (11) 3.72 (10) -2.19 0.89 0.01 
          PRM functional small airway disease, mean ∆ (SD)d,e,f,h,j    0.96 (9) 2.12 (8) -1.20 0.77 0.12 
Airway Thickening Progression      
          SRWA-Pi10 (SD), mean ∆ (SD)d,e,f,h,j 0.08 (0.36) 0.03 (0.34) 0.04 0.06 0.54 
Abbreviations: COPD chronic obstructive pulmonary disease; yr year; SD standard deviation; FEV1 forced expiratory volume in the first second; BD 
bronchodilator; FVC forced vital capacity; CT computed tomography; PRM parametric response mapping; HU Hounsfield units;  SRWA-Pi10 square root wall 
area of a hypothetical airway with 10mm internal perimeter. a Each row is a separate model: b Logistic regression with odds ratio (OR), 95 % confidence interval 
(CI); c Linear regression and d Linear mixed model with beta coefficient (β), standard error (SE). Adjusted for: e pack-years of smoking; f gender, age, race; g 
FEV1 % predicted; h current smoking; i height; j scanner model, BMI; k data available for only a portion of the population. 
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FIGURES 
 
Figure 1 - Overlapping numbers of subjects as categorized for this study by history of childhood pneumonia, childhood asthma or asthma-COPD 
overlap (ACO).  
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